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Hypoxia alters expression of Zebrafish
Microtubule-associated protein Tau
(mapta, maptb) gene transcripts
Seyyed Hani Moussavi Nik1,6*, Morgan Newman1,6, Swamynathan Ganesan1,6, Mengqi Chen2, Ralph Martins2,3,4,
Giuseppe Verdile2,3,4,5 and Michael Lardelli1,6
Abstract
Background: Microtubule-associated protein tau (MAPT) is abundant in neurons and functions in assembly and
stabilization of microtubules to maintain cytoskeletal structure. Human MAPT transcripts undergo alternative splicing
to produce 3R and 4R isoforms normally present at approximately equal levels in the adult brain. Imbalance of the
3R-4R isoform ratio can affect microtubule binding and assembly and may promote tau hyperphosphorylation and
neurofibrillary tangle formation as seen in neurodegenerative diseases such as frontotemporal dementia (FTD) and
Alzheimer’s disease (AD). Conditions involving hypoxia such as cerebral ischemia and stroke can promote similar
tau pathology but whether hypoxic conditions cause changes in MAPT isoform formation has not been widely
explored. We previously identified two paralogues (co-orthologues) of MAPT in zebrafish, mapta and maptb.
Results: In this study we assess the splicing of transcripts of these genes in adult zebrafish brain under hypoxic
conditions. We find hypoxia causes increases in particular mapta and maptb transcript isoforms, particularly the 6R
and 4R isoforms of mapta and maptb respectively. Expression of the zebrafish orthologue of human TRA2B, tra2b,
that encodes a protein binding to MAPT transcripts and regulating splicing, was reduced under hypoxic conditions,
similar to observations in AD brain.
Conclusion: Overall, our findings indicate that hypoxia can alter splicing of zebrafish MAPT co-orthologues promoting
formation of longer transcripts and possibly generating Mapt proteins more prone to hyperphosphorylation. This
supports the use of zebrafish to provide insight into the mechanisms regulating MAPT transcript splicing under
conditions that promote neuronal dysfunction and degeneration.
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Background
The MICROTUBULE-ASSOCIATED PROTEIN TAU
(MAPT) gene encodes the soluble tau protein that is
abundant in neurons and functions to assemble and
stabilize microtubules to maintain cytoskeletal structure
[1]. As a result of alternative splicing of MAPT transcripts,
six tau protein isoforms ranging from 352 to 441 amino
acid residues in length are generated and expressed in
the human brain. The isoforms differ by the regulated
inclusion or exclusion of two regions of sequence near the
N-terminus and the possession of either three (3R) or four
(4R) repeat regions, (corresponding to the microtubule-
binding domains), towards the C-terminus of tau [2]. The
3R isoform is generated from mRNAs lacking exon 10,
while mRNAs containing exon 10 encode 4R tau. These
isoforms are normally present at approximately equal
levels in the adult human brain [3]. Changes in this
isoform ratio and post-translational modifications of
the 3R and 4R isoforms affect microtubule binding and
assembly [4,5].
Dysregulation of tau splicing is often observed in
neurodegenerative diseases with aberrant tau deposition,
including frontotemporal dementia (FTD), Pick disease
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(PiD), progressive supranuclear palsy (PSP) [6] and
Alzheimer’s disease (AD) [7]. Mutations reported in FTD
cause aberrant exon 10 splicing, resulting in altered 4R/3R
tau ratios [8,9]. In PSP, aggregates of 4R tau predominate,
whereas 3R isoforms are found in excess in Pick bodies
in the majority of cases of PiD [10,11]. In AD brains, in-
creases in 4R tau isoforms have been reported resulting
in altered 4R/3R tau ratios [12]. Neurofibrillary tangles
(NFTs), a major pathological hallmark of the AD brain,
can result from the phosphorylation of 3R tau, 4R tau or
both [13,14]. Thus, any alternations in the levels of these
isoforms could promote tangle formation and disease
progression. It should be noted that changes in tau
protein isoform ratios could result both from changes
in the alternative splicing of transcripts and differential
changes in the stability of their protein products.
Conditions such as cerebral ischemia and stroke that
result in hypoxic conditions in affected brain areas can
promote tau hyperphosphorylation and formation of NFTs.
Acute hypoxic conditions have been shown to activate
kinases that phosphorylate tau resulting in accumula-
tion of phosphorylated tau in neurons [15]. In a rodent
stroke model, hyperphosphorylated tau accumulated in
neurons of the cerebral cortex in areas where ischemic
damage was prominent. This was associated with the up-
regulation of the tau phosphorylating enzyme CdK5, and
the consequent promotion of the formation of filaments
similar to those present in human neurodegenerative
tauopathies [16]. It stands to reason that increases in tau
isoforms may also contribute to this process by increasing
the availability of the tau substrate to phosphorylating
enzymes.
The zebrafish, Danio rerio, is an emerging model or-
ganism for the study of neurodegenerative disease [17].
Zebrafish embryos represent normal collections of cells
in which complex and subtle manipulations of gene
activity can be performed to facilitate analyses of genes
involved in human disease. The zebrafish genome is
extensively annotated and regions of conservation of
chromosomal synteny between humans and zebrafish
have been defined [18]. In many cases zebrafish genes
are identifiable that are clear orthologues of human genes.
For example, the AD-relevant PRESENILIN genes (PSEN1
and PSEN2) have zebrafish orthologues of psen1 [19]
and psen2 [20] respectively. Tau phosphorylation and
subsequent toxicity has been reported in zebrafish over-
expressing the FTD associated human tau mutation,
P301L [21,22]. However this model does not reflect the
pathology of other dementias such as AD where factors
that regulate levels of wild-type tau isoforms promote
hyper-phosphorylation and neurodegeneration.
We have previously identified two paralogues (co-ortho-
logues) of MAPT in zebrafish, denoted mapta and maptb
and have shown that both genes are expressed in the
developing central nervous system [23]. (Teleosts appear
to have undergone an additional round of genome dupli-
cation since their separation from the tetrapod lineage
followed by loss of many of the duplicated genes [18]).
Similar to human MAPT, a complex pattern of alternative
splicing of the mapta and maptb transcripts occurs.
Zebrafish mapta gives rise to transcripts encoding 4R-6R
isoforms, whereas maptb is predominantly expressed as a
3R isoform [23] (Figure 1) and is also alternatively spliced
to form a “big tau” isoform. In mammals “big tau” is
expressed in the peripheral nervous system and other
tissues [24-26] while in zebrafish we observed “big tau”
expression (at 24 hours post fertilization, hpf ) in the
trigeminal ganglion and dorsal spinal cord neurons (pos-
sibly dorsal sensory neurons) [23]. However, whether hyp-
oxic conditions lead to changes in tau isoform expression
has not been widely explored in zebrafish. In the work
described in this paper we extend our examination of
expression of the zebrafish tau co-orthologues to study
their response to actual hypoxia in adult fish brains and
to chemical mimicry of hypoxia in explanted adult fish
brains. We observe increases in the overall levels of both
mapta and maptb transcripts due to specific increases in
the levels of mapta 6R and maptb 4R transcript isoforms.
This is consistent with dramatically decreased levels of
transcripts of the zebrafish orthologue of the human
TRA2B gene that codes for a splicing factor regulating
alternative splicing of MAPT transcripts in human cells
[12]. We also observe an apparent increase under hyp-
oxia in the levels of shorter transcripts of maptb relative
to “big tau” transcripts of this gene. Overall, our find-
ings indicate that hypoxia can alter splicing of zebrafish
MAPT co-orthologues promoting formation of longer
transcripts and possibly generating Mapt proteins more
prone to hyperphosphorylation. This supports the use
of zebrafish to provide insight into the mechanisms
regulating MAPT transcript splicing under conditions
that promote neuronal dysfunction and degeneration.
Results
To determine whether hypoxic conditions regulate alter-
native splicing in MAPT co-orthologues in zebrafish, levels
of mapta and maptb transcripts were assessed in adult
zebrafish brains under conditions of actual hypoxia or in
explanted adult brains subjected to chemical mimicry of
hypoxia caused by NaN3.
In studies of hypoxia it is common to use chemical
agents that can mimic (partially) hypoxic conditions
(also known as “chemical hypoxia”). Agents commonly
used are cobalt chloride (CoCl2), nickel chloride (NiCl2)
and NaN3. Azides, including NaN3, have an action on the
respiratory chain very similar to that of cyanide. We have
previously shown that exposure to aqueous solutions of
NaN3 can induce hypoxia-like responses in zebrafish [27].
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Figure 1 Splicing isoforms of mapta and maptb mRNA transcripts. Grey and white boxes indicate exons subject to alternative splicing. The
black lines below exons indicate those encoding tubulin-binding motifs. Arrows indicate the approximate binding sites of primers used in qPCR
analyses of splicing isoforms. (A) Exon structure of mapta.isoforms (B) Exon structure of maptb isoforms.
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Exposure of adult fish to hypoxia or exposure of explanted
adult brains to chemical mimicry of hypoxia increases the
overall expression of tau transcripts in zebrafish brains.
This was shown by qPCR measurement involving amplifi-
cation of exonic sequence included in all transcripts of
mapta or maptb (i.e. exon 6 of both genes – see Figure 2A
and 2B). We also observed that the pattern of tau tran-
script splicing differs between hypoxia-exposed brains and
controls. In terms of contributing isoforms, expression of
the mapta 6R isoform was significantly increased, while
expression of the mapta 4R isoform showed a significant
decrease under hypoxia (Figure 2A). We also observed a
significantly increased level of expression of maptb 4R
transcripts, while expression of maptb 3R transcripts also
showed a significant decrease under hypoxia (Figure 2B).
An increase in expression of maptb 4R but not 3R corre-
sponds to an overall increase in the 4R/3R ratio of tau
transcripts (Figure 2B).
In rats (and humans) Mapt exon 4a contains a large
open reading frame. Inclusion of this exonic sequence in
MAPT mRNAs allows translation of “big tau” protein.
Exon 3 of zebrafish maptb appears to be equivalent to
rat exon 4a in size although no sequence homology is
observed. Like rat MAPT exon 4a, zebrafish maptb exon
3 is subject to alternative splicing [23]. Therefore, we
performed qPCR to test whether this alternative spli-
cing event is also influenced by hypoxic conditions.
We observed that exclusion of exon 3 (here denoted as
maptb −3) from zebrafish maptb transcripts is signifi-
cantly increased under hypoxia and chemical mimicry
of hypoxia when compared with inclusion of exon 3
(here denoted as maptb +3) (Figure 2C).
In humans, differential splicing of MAPT transcripts in
response to hypoxia can occur due to decreased binding
of TRA2 protein to RNA [28]. The TRA2 gene is dupli-
cated in vertebrates, resulting in two TRA2 proteins with
aprpoximately 63% amino acid residue identity in humans
[29]. These proteins are denoted TRA2A encoded by the
TRA2A gene and TRA2B protein encoded by the gene
TRA2B (also known as SFRS10). Nuclear magnetic res-
onance (NMR) analyses have recently shown that the
optimal core RNA target sequence for binding TRA2B
protein is AGAA. Conrad et al. [12] observed AD-specific
changes in TRA2B expression, suggesting a potential
mechanism for altered tau in AD. Suh et al. [28] also ob-
served a decrease in mouse Tra2b expression leading to a
decrease in exon 10 exclusion and 3R-tau expression in
cortical neurons after transient occlusion of the middle
cerebral artery in mice. To examine whether this behavior
is conserved for the zebrafish mapta and maptb genes we
first observed whether hypoxia alters expression of the
TRA2B orthologous gene, tra2b, in zebrafish brains. As
shown in Figure 2D both actual hypoxia and chemical
mimicry of hypoxia lead to decreased tra2b transcript
levels presumably indicating reduction in the splice-
regulating activity of Tra2b protein. We then examined
whether the zebrafish mapta and maptb genes possess
potential Tra2b binding sites within exons encoding
tubulin-binding repeats and subject to alternative splicing.
Using the online software, ESE finder (http://genes.mit.
edu/burgelab/rescue-ese/) [30], zebrafish sequences for
mapta exon 8 and maptb exon 9 were examined for puta-
tive tra2b binding sites. We found multiple exonic splicing
enhancers (ESEs) but, for each gene, only one appeared
significantly similar to the human TRA2B-binding site
(Figure 3).
Discussion
The human MAPT gene is located on chromosome 17
and contains 16 exons. Alternative splicing of the primary
transcript leads to a family of mRNAs, encoding different
protein isoforms. In adult human brain, six isoforms are
expressed, produced by alternative splicing of exons 2, 3,
and 10. Tau isoforms in the CNS contain either three or
four copies of a tandem repeat containing tubulin-binding
sequences (encoded by exon 10), referred to as 3R and
4R-tau [24]. Optional inclusion of exon 2, or exons 2 and
3, gives rise to N-terminal inclusions of 29 or 58 amino
acid residues respectively [24].
In this study we provide evidence that exposure to
actual hypoxia and to chemical mimicry of hypoxia
leads to overall increases in tau transcript levels and,
simultaneously, marked relative changes in the alterna-
tive splicing of tau transcripts in adult zebrafish brains.
Our results revealed that exposure to acute levels of
actual hypoxia or chemical mimicry of hypoxia shifts
the production of the predominantly expressed 3R
transcript isoform of maptb towards formation of the
4R isoform, thus altering the 3R to 4R ratio. The precise
regulation of the ratio of expression of 3R relative to 4R
MAPT isoforms in human brain has been proposed to be
critical for maintaining normal brain function [31]. The
disruption of this balance has been found to be correlated
with tauopathies [8,32]. We also observed a significant
increase in expression of the 6R transcript isoform of
zebrafish mapta relative to the mapta 4R transcript.
As far as the behavior in alternative splicing of exons
coding for tubulin-binding domain sequences is concerned,
our data are in agreement with those of Conrad et al. [12]
and Ichihara et al. showing that, in AD brains, the expres-
sion level of exon 10 is altered [33].
Imbalance of the 4R-3R tau isoform ratio has been ob-
served in tauopathies such as FTDP-17 [8], PSP [10], and
PiD [34]. An altered 4R-3R tau isoform ratio has also been
reported in the spinal cord after sciatic nerve axotomy
[35]. Suh et al. [28] reported that cerebral ischemia
changes the ratio of 4R-3R tau mRNAs and protein levels
as well as causing tau hyperphosphorylation. Changes in
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Figure 2 (See legend on next page.)
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tau isoform ratio and phosphorylation status can cause
defects in the central nervous system by affecting
microtubule dynamics and axonal transport resulting
in neuronal loss [4]. Therefore, it is conceivable that an
alteration of tau isoform ratio and increased tau hyper-
phosphorylation after brain ischemic insult may contrib-
ute to the prevalence of AD in stroke patients [36,37].
Exon 10 of the human MAPT gene, is flanked by a
large intron 9 (13.6 kb) and intron 10 (3.8 kb), and has a
stem-loop structure which spans the 5′ splice sites, which
can sequester the 5′ splice site and leads to the use of al-
ternative 5′ splice sites [38]. Thus exon 10 can be included
or skipped to produce tau proteins with or without exon
10, depending on the action of trans-acting or cis-elements
located in exon 10. Hutton M, 1998 [8] The pre-mRNA
splicing factor Tra2b was shown to promote MAPT exon
10 splicing [39]. Levels of Tra2b protein were found to be
reduced in AD brains [12]. Decreased levels of this spli-
cing factor were also observed by Suh et al. [28] in cortical
neurons and in mouse cerebral cortex following hypoxic-
ischemic injury. Thus, decreased Tra2b expression under
hypoxia may contribute to a shift in 4R-3R tau isoform
ratio by increasing incorporation of exon 10 into mature
MAPT mRNA. Consistent with this we detected putative
Tra2b-binding sites in exon 8 of mapta and exon 9 of
maptb. We also saw decreased expression of tra2b mRNA
under hypoxic conditions.
High molecular weight (HMW) tau isoforms “big
tau” have been detected in the neurons of the adult rat
peripheral nervous system (PNS), optic nerve, spinal
cord, several neuronal cell lines including PC12 and
neuroblastoma N115 [24] and non-neuronal tissues
[25,26]. “Big tau” appears to be the only tau isoform
expressed in adult dorsal root ganglia (DRG) [24,40].
“Big tau” is encoded by an 8 kb mRNA containing an
additional exon 4a that is not present in any other tau
isoforms. “Big tau” expression is developmentally regu-
lated. It is expressed late in fetal life and its expression
increases postnatally [24]. Its presence has been corre-
lated with increased neurite stability in adult DRG [40].
Several studies have investigated “big tau” expression in
non-neuronal tissues in AD patients but did not observe
any significant changes [25,26]. Chen et al. [23] described
an alternative splicing event involving maptb exon 3,
which appears to be equivalent to human MAPT exon 4a.
In our experiments we observed that hypoxia significantly
increases the level of maptb transcripts from which exon
3 sequence is excluded but does not appear to change
levels of the “big tau” form of maptb transcripts. However,
we cannot exclude the possibility that this apparent
increase in maptb expression with decreased exon 3 inclu-
sion may be due to increased expression of the shorter
transcript isoform in cells that do not express big tau,
rather than a change in the ratio of splicing to form
shorter transcript relative to “big tau” transcript within
cells expressing both transcripts.
Conclusion
Overall, our findings show that exposure of zebrafish
brains to actual hypoxia or chemical mimicry of hypoxia
can produce changes in the expression ratio of different
tau isoforms. These changes are similar to those observed
in a number of neurodegenerative diseases and thus sup-
port the use of zebrafish as a model for providing further
insight into the mechanisms underlying these disease
processes.
Figure 3 Sequences from human MAPT and zebrafish mapta and maptb were analysed for the presence of possible Tra2B binding sites
using the online software ESE finder (http://genes.mit.edu/burgelab/rescue-ese/). Bold, underlined letters are putative Tra2b-binding sites.
(See figure on previous page.)
Figure 2 qPCR analyses of the expression of A) Measurement of mapta exon 6 levels gives the combined expression of all mapta
transcripts in zebrafish brains. qPCRs to determine relative mapta 6R and 4R isoform levels show increased and decreased expression under
hypoxia respectively. B) Measurement of maptb exon 6 levels gives the combined expression of all maptb transcripts in zebrafish brains. qPCRs to
determine relative maptb 4R and 3R isoform levels show increased and decreased expression under hypoxia respectively. C) maptb +3 (“big tau”)
is decreased relative to maptb −3 under hypoxia. D) tra2b transcript levels under normoxia are higher relative to those under hypoxia or chemical
mimicry of hypoxia (sodium azide exposure). Expression ratios for mapta and maptb are shown relative to normoxia (the normoxia expression
level is normalized to eef1a1l1). ***P ≤ 0.0001; **P≤ 0.001; ****P ≤ 0.00001. Error bars represent standard error of the mean.
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Methods
Ethics
This work was conducted under the auspices of The
Animal Ethics Committee of The University of Adelaide
and in accordance with EC Directive 86/609/EEC for
animal experiments and the Uniform Requirements for
Manuscripts Submitted to Biomedical Journals.
Zebrafish husbandry and experimental procedures
Danio rerio were bred and maintained at 28°C on a 14 h
light/10 h dark cycle [41]. Adult zebrafish (AB strain) at
approximately 1 year of age were used for all experiments
(n = 12). Fish for analysis were not selected on the basis of
sex. For chemical mimicry of hypoxia adult explant brain
tissue was exposed to 100 μM of sodium azide (NaN3,
Sigma-Aldrich CHEMIE Gmbh, Steinheim, Germany) in
DMEM medium for 3 hours. Untreated adult zebrafish
brain explants that were dissected from zebrafish in the
same way as for the treated adult zebrafish brains were
used as in vitro controls. In the experiments conducted
under low oxygen conditions, oxygen was depleted by
bubbling nitrogen gas through the medium. Oxygen con-
centrations were then measured using a dissolved oxygen
meter (DO 6+, EUTECH instruments, Singapore). The
dissolved oxygen level in the actual hypoxia group was
measured to be 1.15 ± 0.6 mg/l; whereas the normal ambi-
ent oxygen level was 6.6 ± 0.45 mg/l [27,42]. Zebrafish
were exposed to actual hypoxia for 3 hours. Briefly, after
each hypoxia trial, the animals were euthanized by
hypothermic shock and then decapitated to remove the
brain. Total RNA was extracted from samples mentioned
above using the QIAGEN RNeasy mini kit (QIAGEN,
GmbH, Hilden, Germany) and stored at −80°C for further
analysis. RNA concentration was determined with a
NanoVue™ UV–vis spectrophotometer (GE Healthcare
Life Sciences, Fairfield, USA). To insure quality of RNA,
RNA samples were electrophoresed on 1% TBE agarose
gels. 700 ng of total RNA were used to synthesize 25 μL of
first-strand cDNA by reverse transcription (SuperScript®
ΙΙΙ First-Strand DNA synthesis kit; Invitrogen, Camarillo,
USA).
Quantitative real-time PCR for detection
The relative standard curve method for quantification was
used to determine the expression of experimental samples
compared to a basis sample. For experimental samples,
target quantity was determined from the standard curve
and then compared to the basis sample to determine fold
changes in expression. Gene-specific primers were designed
for amplification of target cDNA and the cDNA from the
ubiquitously expressed control gene eef1a1a. The reaction
mixture consisted of 50 ng/μl of cDNA, 18 μM of forward
and reverse primers and Power SYBR green master mix
PCR solution (Applied Biosystems, Warrington, UK).
Table 1 Gene specific primers used for qPCR
Gene/transcript isoform Accession number Sequence Amplicon size
eef1a1l1 (F) NM_131263.1 5′-CTGGAGGCCAGCTCAAACAT-3′ 87 bp
eef1a1l1 (R) 5′-ATCAAGAAGAGTAGTACCGCTAGC-3′
tra2b (F) NM_201197 5′-GCAGACGACATATTGGTGACC-3′ 155 bp
tra2b (R) 5′-TGACTGCTGGTCGTACACAATG-3′
maptb 4R (F) XM_005171601 5′-AAGATCGGCTCCACTGAGAACC-3′ 194 bp
maptb 4R (R) 5′-GATCCAACCTTTGACTGGGCTT-3′
maptb 3R (F) XM_005171601 5′-GGGAAGGGGTGGAAATGTC-3′ 140 bp
maptb 3R (R) 5′-GATCCAACCTTTGACTGGGCTT-3′
mapta 6R (F) XM_001340530 5′-TCGTCACAAACCAGGTGGAG-3′ 152 bp
mapta 6R (R) 5′-GCTCACGGAACGTCAGTTTG-3′
mapta 4R (F) XM_001340530 5′-CGGAGGTGGAAAATTGAGTCAC-3′ 100 bp
mapta 4R (F) 5′-CTCCTCCAGGGACACAATTTCT-3′
maptb −3 (F) XM_005171601 5′-GAAGCCAAGGCTGGAGCA-3′ 120 bp
maptb −3 (R) 5′-CTGGGGATGCCTGTGACTGA-3′
maptb +3 (F) XM_005171601 5′-CCGGCAACAACATAGCATCTG-3′ 140 bp
maptb +3 (R) 5′-CACCGGGAGTGAATGTGGC-3′
mapta Ex.6 (F) XM_001340530 5′-CCTAAATCTCCTGCCAGCAAG-3′ 117 bp
mapta Ex.6 (R) 5′-TGTGGGCGAACGGTTCTT-3′
maptb Ex.6 (F) XM_005171601 5′-CAAATCACCTGGCTCGCTG-3′ 114 bp
maptb Ex.6(R) 5′-GGTTGGTGTTTGAGGTTCTCAGTG-3′
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To generate the standard curve cDNA was serially
diluted (100 ng, 50 ng, 25 ng, 12.5 ng). Each sample
and standard curve reaction was performed in triplicate
for the control gene and experimental genes. Amplifica-
tion conditions were 2 min at 50°C followed by 10 min at
95°C and then 40–45 cycles of 15 s at 95°C and 1 min at
60°C. Amplification was performed on an ABI 7000 Se-
quence Detection System (Applied Biosystems) using 96
well plates. Cycle thresholds obtained from each triplicate
were averaged and normalized against the expression of
eef1a1l1, which has previously been demonstrated to show
unchanged levels of expression under hypoxia in embryos
at 6, 12, 48 and 72 hpf and in adult gills [43]. Each experi-
mental sample was then compared to the basis sample to
determine the fold change of expression. The primers
used for quantitative real-time PCR analysis of relative
zebrafish mapta/b mRNA levels are shown in Table 1. To
reduce possible interference from unspliced RNA and/or
contaminating genomic DNA primers were designed to
bind in cDNA over exon-exon boundaries. All qPCRs
were performed according to MIQE guidelines [44].
Statistical analysis of data
Means and standard deviations were calculated for all
variables using conventional methods. Two-way ANOVA
was used to evaluate significant differences between
normoxia and samples from actual hypoxia or chemical
mimicry of hypoxia. p-Values are shown in the figure
legends, a criterion alpha level of P < 0.05 was used for all
statistical comparisons. All qPCR assays were done in
three biological replicates with three qPCRs per biological
replicate). All the data were analysed using GraphPad
Prism version 6.0 (GraphPad Prism, La Jolla, CA).
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